早期类风湿关节炎不同COBRA样强化缓解诱导方案的两年成本效果:基于CareRA随机对照试验的附加研究
基于CareRA试验379例早期RA患者的2年开放标签实用性随机对照数据,从医疗保健视角计算增量成本效用。高危组中COBRA Slim相比COBRA Classic和COBRA Avant-Garde成本更低且QALYs略优,Slim占优;低危组中Slim相比TSU成本更低且QALYs更高,Slim占优。结论在生物类似药价格下稳健。
要点
- 高危早期RA中,COBRA Slim在2年时成本低于Classic和Avant-Garde且健康效用相当。
- 低危早期RA中,COBRA Slim相比TSU成本更低且QALYs更高。
- 结果在采用生物类似药价格时保持稳健。
核心结论
- 甲氨蝶呤联合糖皮质激素桥接方案在初始治疗2年后,相比更强化的降阶联合策略或常规升阶方案成本更低且健康效用相当。
研究设计与样本
- 基于2年开放标签实用性随机对照CareRA试验的附加成本效用分析,意向治疗人群n=379,从医疗保健视角计算增量成本效用。
主要发现
- 高危组中Classic相比Slim增量成本Δk€1.464(95%CI -0.198至3.127),QALYsΔ-0.002(95%CI -0.086至0.082)。
- 高危组中Avant-Garde相比Slim增量成本Δk€0.636(95%CI -0.987至2.258),QALYsΔ-0.009(95%CI -0.102至0.084),Slim占优。
- 低危组中Slim相比TSU增量成本Δk€-0.617(95%CI -2.799至1.566),QALYsΔ0.141(95%CI 0.008至0.274),Slim占优。
- 结果在采用生物类似药价格时保持稳健。
关键数值与推荐
- 高危组中COBRA Slim相比COBRA Classic和COBRA Avant-Garde成本更低且QALYs略优,Slim占优。
- 低危组中COBRA Slim相比Tight-Step-Up成本更低且QALYs更高,Slim占优。
临床怎么用
- 早期RA高危患者可优先考虑甲氨蝶呤联合糖皮质激素桥接的COBRA Slim方案,以更低成本获得相当健康效用。
- 早期RA低危患者采用COBRA Slim相比常规升阶方案更具成本效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the cost-effectiveness of treat-to-target strategies among recently diagnosed patients with rheumatoid arthritis (RA) using methotrexate (MTX) and a step-down glucocorticoid (GC) scheme (COBRA Slim) compared with (1) this combination with either sulphasalazine (COBRA Classic) or leflunomide (COBRA Avant-Garde) in high-risk patients and (2) MTX without GCs (Tight-Step-Up, TSU) in low-risk patients. METHODS: The incremental cost-utility was calculated from a healthcare perspective in the intention-to-treat population (n=379) of the 2-year open-label pragmatic randomised controlled Care in early RA trial. Healthcare costs were collected prospectively through electronic trial records. Quality-adjusted life years (QALYs) were estimated using mapping algorithms for EuroQoL-5 Dimension. Multiple imputation was used to handle missing data and bootstrapping to calculate CIs. Robustness was tested with biological disease-modifying antirheumatic drugs at biosimilar prices. RESULTS: In the high-risk group, Classic (∆k€1.464, 95% CI -0.198 to 3.127) and Avant-Garde (∆k€0.636, 95% CI -0.987 to 2.258) were more expensive compared with Slim and QALYs were slightly worse for Classic (∆-0.002, 95% CI -0.086 to 0.082) and Avant-Garde (∆-0.009, 95% CI -0.102 to 0.084). This resulted in the domination of Classic and Avant-Garde by Slim. In the low-risk group, Slim was cheaper (∆k€-0.617, 95% CI -2.799 to 1.566) and QALYs were higher (∆0.141, 95% CI 0.008 to 0.274) compared with TSU, indicating Slim dominated. Results were robust against the price of biosimilars. CONCLUSIONS: The combination of MTX with a GC bridging scheme is less expensive with comparable health utility than more intensive step-down combination strategies or a conventional step-up approach 2 years after initial treatment. TRIAL REGISTRATION NUMBER: NCT01172639.
引用
- Pazmino S, Boonen A, Stouten V, et al. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial. Ann Rheum Dis. 2020. PMID: 32241795. doi:10.1136/annrheumdis-2019-216874
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。